vTv Therapeutics Inc. (VTVT) company profile
Close on Nov 18, 2026Market cap $64.17MP/E –Yield –
About vTv Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical firm that discovers and develops oral therapies for metabolic and inflammatory conditions. Its primary drug candidate is cadisegliatin, an oral liver-selective glucokinase activator in late-stage development as an add-on treatment to insulin for individuals with type 1 and type 2 diabetes. Its broader research pipeline features oral small molecules including a GLP-1 receptor agonist for diabetes management, a preclinical RAGE antagonist, Nrf2 pathway activators for inflammation, and a globally licensed PDE4 inhibitor. The company targets patients suffering from chronic metabolic and autoimmune disorders, while collaborating with commercial partners and research institutions.
The company conducts clinical development programs and maintains commercial partnerships across the United States, the Middle East, Africa, Central Asia, and the Pacific Rim. Its clinical operations encompass multiple studies, including a Phase 3 study evaluating 150 patients and a 300-patient regional study. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of vTv Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- vTv Therapeutics Inc.
- Founded
- 2015
- Headquarters
- High Point, NC
- Address
- 3980 Premier Dr, Suite 310 27265
- Phone
- (336) 841-0300
- Website
- vtvtherapeutics.com
- Employees
- 26, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Detroit, Michigan
Stock & identifiers
- Ticker
- VTVT
- Exchange
- Nasdaq
- IPO date
- Jul 31, 2015
- Shares outstanding
- 4M, Aug 6, 2026
- Public float
- $22.36M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, Nov 21, 2023
- SEC CIK
- 1641489
- CUSIP
- 918385204
- ISIN
- US9183852048
- FIGI
- BBG009DT9XJ0
- Share class FIGI
- BBG009DT9XK8
- LEI
- 549300WQE5EI9R35SE66
- EIN
- 47-3916571
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul J. Sekhri | Pres, CEO and Exec Chairperson, Director | 392,212 |
| Michael Stephen Tung | EVP & CFO | – |
| Barry K. Brown | Chief Accounting Officer | 4 |
| Felix Baker | Director | – |
| Brothers Life Sciences LP Baker | Director | – |
| Bros. Advisors (GP) LLC Baker | Director | – |
| 667, L.P. | Director | 89,254 |
| Daniel K. Spiegelman | Director | – |
| Fahed Al-Marzooqi | Director | – |
| Srinivas Akkaraju | Director | 312,784 |
| Bros. Advisors Lp Baker | Director | 142,135 |
| Julian Baker | Director | 12,368 |
| Anne M. Phillips | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.64M | $5.73M | $1.29M | $143 | – |
| FY2024 | $3.86M | $1.98M | $1.52M | $51 | – |
| FY2023 | $1.33M | $697.40K | $670.25K | $42 | – |
| FY2022 | $373.66K | $335.21K | $393.53K | $65 | – |
| FY2022 Nelson | $680.74K | $647.87K | $393.53K | $65 | – |
| FY2022 Nelson And Prasad | $1.68M | -$63.28K | $393.53K | $65 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Paul Sekhri President and Chief Executive Officer | $673.00K | $5.60M | $343.23K | $20.31K | $6.64M | +72% |
| Michael Tung Executive Vice President and Chief Financial Officer | $279.55K | $2.02M | $135.05K | $8.66K | $2.44M | – |
| Steven Tuch Former Executive Vice President and Chief Financial Officer | $107.39K | – | – | $34.91K | $142.30K | -91% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 31, 2015
- Offer price
- $15.00
- Securities offered
- 7,812,500
- Gross proceeds
- $117.19M
- Exchange
- Nasdaq
- First trading day
- Jul 30, 2015
- First-day close
- $10.89-27.4%
- Lock-up ends (est.)
- Jan 26, 2016
“The initial public offering price is $15.00 per ordinary share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025 we had twenty-six employees and none of our employees are represented by a labor union, and we consider our employee relations to be good.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?